Table S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Authors:
- Racha HosniRHRacha Hosni
- Niklas KlümperNKNiklas Klümper
- Christine SandersCSChristine Sanders
- Sana HosniSHSana Hosni
- Vittorio BranchiVBVittorio Branchi
- Alexander SemaanASAlexander Semaan
- Abdullah AlajatiAAAbdullah Alajati
- Natalie PelusiNPNatalie Pelusi
- Susanna S. NgSNSusanna S. Ng
- Damian J. RalserDRDamian J. Ralser
- Saif-Eldin AbedellatifSaif-Eldin Abedellatif
- Hanno MatthaeiHMHanno Matthaei
Open Access
- 3 November 2025
- other
- Published by American Association for Cancer Research (AACR)